{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:27:15Z","timestamp":1762018035961,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.4158\/ep171769.or","type":"journal-article","created":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T10:56:13Z","timestamp":1502967373000},"page":"1316-1324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparing Clinical Outcomes and Costs for Different Treatment Intensification Approaches in Patients with Type 2 Diabetes Uncontrolled On Basal Insulin: Adding Glucagon-Like Peptide 1 Receptor Agonists Versus Adding Rapid-Acting Insulin or Increasing Basal Insulin Dose"],"prefix":"10.1016","volume":"23","author":[{"given":"Philip","family":"Levin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damion","family":"Nero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bong-Chul","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP171769.OR_bb0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.4158\/EP171769.OR_bb0015","first-page":"S1","article-title":"Standards of Medical Care in Diabetes\u20132017","volume":"40","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"key":"10.4158\/EP171769.OR_bb0020","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/S0140-6736(14)61335-0","article-title":"Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis","volume":"384","author":"Eng","year":"2014","journal-title":"Lancet"},{"key":"10.4158\/EP171769.OR_bb0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/dom.12025","article-title":"Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature","volume":"15","author":"Balena","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP171769.OR_bb0030","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jdiacomp.2014.07.007","article-title":"Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis","volume":"28","author":"Charbonnel","year":"2014","journal-title":"J Diabetes Complications"},{"key":"10.4158\/EP171769.OR_bb0035","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc14-0876","article-title":"Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes","volume":"37","author":"Diamant","year":"2014","journal-title":"Diabetes Care"},{"key":"10.4158\/EP171769.OR_bb0040","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2337\/dc14-0001","article-title":"Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglu-tide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"10.4158\/EP171769.OR_bb0045","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.2337\/dc16-0014","article-title":"Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 Trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"issue":"6 suppl 1","key":"10.4158\/EP171769.OR_bb0050","doi-asserted-by":"crossref","first-page":"6S21","DOI":"10.1016\/S1262-3636(16)30005-2","article-title":"Options for intensification of basal insulin in type 2 diabetes: premeal insulin or short-acting GLP-1 receptor agonists?","volume":"41","author":"Darmon","year":"2015","journal-title":"Diabetes Metabol"},{"key":"10.4158\/EP171769.OR_bb0055","unstructured":"Truven Health Analytics. Available at: http:\/\/truvenhealth.com\/markets\/life-sciences\/products\/data-tools\/marketscan-databases. Accessed October 31, 2016."},{"key":"10.4158\/EP171769.OR_bb0060","unstructured":"National Committee for Quality AssuranceHEDIS\u00ae Measures. Available at: http:\/\/www.ncqa.org\/hedis-quality-measurement\/hedis-measures. Accessed October 26, 2016."},{"key":"10.4158\/EP171769.OR_bb0065","unstructured":"Centers for Disease Control and PreventionInternational Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Available at: www.cdc.gov\/nchs\/icd\/icd9cm.htm. Accessed October 31, 2016."},{"key":"10.4158\/EP171769.OR_bb0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2337\/dc14-1329","article-title":"Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial","volume":"38","author":"ORIGIN Trial Investigators","year":"2015","journal-title":"Diabetes Care"},{"key":"10.4158\/EP171769.OR_bb0075","first-page":"15","article-title":"Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization","volume":"14","author":"Young","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.4158\/EP171769.OR_bb0080","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"key":"10.4158\/EP171769.OR_bb0085","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1161\/CIRCULATIONAHA.113.006985","article-title":"Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease","volume":"129","author":"Smilowitz","year":"2014","journal-title":"Circulation"},{"key":"10.4158\/EP171769.OR_bb0090","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.4158\/EP171769.OR_bb0095","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4158\/EP14290.OR","article-title":"Adding rapid-acting insulin or glp-1 receptor agonist to basal insulin: outcomes in a community setting","volume":"21","author":"Dalal","year":"2015","journal-title":"Endocr Pract"},{"key":"10.4158\/EP171769.OR_bb0100","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12325-016-0470-y","article-title":"Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a Medicare population","volume":"34","author":"Nguyen","year":"2017","journal-title":"Adv Ther"},{"key":"10.4158\/EP171769.OR_bb0105","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP171769.OR_bb0110","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP171769.OR_bb0115","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-017-0499-6","article-title":"A review of the long-term efficacy, and safety of exenatide once weekly for type 2 diabetes","author":"Genovese","year":"2017","journal-title":"Adv Ther"},{"issue":"suppl 2","key":"10.4158\/EP171769.OR_bb0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/pds.3263","article-title":"One-to-many propensity score matching in cohort studies","volume":"21","author":"Rassen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20352204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20352204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:02:54Z","timestamp":1761516174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20352204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1530891X20352204"],"URL":"https:\/\/doi.org\/10.4158\/ep171769.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing Clinical Outcomes and Costs for Different Treatment Intensification Approaches in Patients with Type 2 Diabetes Uncontrolled On Basal Insulin: Adding Glucagon-Like Peptide 1 Receptor Agonists Versus Adding Rapid-Acting Insulin or Increasing Basal Insulin Dose","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP171769.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}